Larimar Therapeutics, Inc. (LRMR) stock
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.23+0.23 (+7.86%)
Close on Nov 18, 2026Market cap $335.02MP/E –Yield –
Larimar Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Larimar Therapeutics's free cash flow for the twelve months ending Jun 30, 2025 was -$92.59M. For fiscal 2025 it was -$113.29M. The highest annual figure on record is -$13.59M in fiscal 2012.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$113.29M | – |
| FY2024 | Dec 31, 2024 | -$71.28M | – |
| FY2023 | Dec 31, 2023 | -$33.62M | – |
| FY2022 | Dec 31, 2022 | -$27.67M | – |
| FY2021 | Dec 31, 2021 | -$42.44M | – |
| FY2020 | Dec 31, 2020 | -$42.26M | – |
| FY2019 | Dec 31, 2019 | -$22.78M | – |
| FY2018 | Dec 31, 2018 | -$51.60M | – |
| FY2017 | Dec 31, 2017 | -$43.84M | – |
| FY2016 | Dec 31, 2016 | -$52.64M | – |
| FY2015 | Dec 31, 2015 | -$60.15M | – |
| FY2014 | Dec 31, 2014 | -$28.30M | – |
| FY2013 | Dec 31, 2013 | -$15.02M | – |
| FY2012 | Dec 31, 2012 | -$13.59M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -$19.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.88M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.93M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.49M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.86M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.23M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.20M | -451.1% |
| Q1 FY2020 | Mar 31, 2020 | -$8.98M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.82M | – |
| Q2 FY2019 | Jun 30, 2019 | $3.48M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.47M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.85M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.15M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.33M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.27M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.10M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.19M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.69M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.67M | – |
| Q3 FY2016 | Sep 30, 2016 | -$11.03M | – |
See a number that looks wrong?